Clinical trials: Immunity to COVID-19
COVID-19 Vaccines
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
The effectiveness of COVID-19 vaccines in reducing the risk of severe COVID-19 is currently demonstrated. In France, since the beginning of the vaccination campaign, 54,266,859 people have received at least one injection (ie.
- Trial name
- COVIBOOSTAnci1 (NCT05405283)
- Testing
- 2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Healthy
COVID-19 Vaccine Response in Treated MS Patients
The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to…
- Trial name
- NCT05060354
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
COVID-19 Vaccine, Cancer
Host Immune Response to Novel RNA COVID-19 Vaccination
To determine the antibody response level in patients with cancer to the COVID-19 vaccination.
- Trial name
- NCT04784689
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Oncology, COVID-19
Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic
This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19…
- Trial name
- OBVIONCO (NCT04437719)
- Testing
- Obvio-19 app
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Community-based Sero-epidemiological Study of COVID-19
Using detailed serial cross-sectional estimates of the age-specific distribution of SARS-CoV-2 Omicron variant-specific antibody positivity levels, the investigators derived age-specific infection attack rates and age-specific…
- Trial name
- NCT05599555
- Testing
- mRNA BNT162b2 vaccine, CoronaVac vaccine
- Where
- Hong Kong
- Volunteers
- 9,600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID-19, Non-specific Effects of Vaccines
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Background: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW).
- Conditions
- COVID-19, Non-specific Effects of Vaccines, Morbidity, Absenteeism
- Trial name
- NCT04373291
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,293 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Relapsing Multiple Sclerosis
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a…
- Trial name
- NCT04847596
- Testing
- Ofatumumab, Covid-19 vaccine
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial
This pilot double-blind randomized controlled trial will test the preliminary efficacy of two doses of a combination of live microbials (probiotics) given to boost the immunity of unvaccinated persons previously infected with…
- Trial name
- NCT04847349
- Testing
- OL-1, standard dose, OL-1, high dose
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19, SARS-CoV-2
Professional's Health in Epidemiological Crisis Covid-19
Introduction: Coronavirus Disease 2019 (COVID-19) has caused a global pandemic. Epidemiological and clinical inter-individual differences, symptomatology, recovery and humoral response against Severe Acute Respiratory Syndrome…
- Trial name
- ProHEpiC-19 (NCT04885478)
- Testing
- Immune response monitoring , blood samples
- Where
- Spain
- Volunteers
- 1,350 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Liver Diseases, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).
- Conditions
- Liver Diseases, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIMPLE (NCT05007665)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Multiple Sclerosis
Covid-19 Vaccine Immune Response in Multiple Sclerosis
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection.
- Trial name
- CoVaR-MS (NCT05269888)
- Testing
- Blood Test 1, Blood Test 2
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Immunology, Allergy
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections.
- Conditions
- Immunology, Allergy, Genetic Diseases, Infectious Diseases
- Trial name
- COVIFERON (NCT06762002)
- Testing
- blood sample
- Where
- 9 sites in France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SARS-CoV-2
Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by…
- Trial name
- SeCo (NCT04370119)
- Testing
- Nasal swab, Serum testing
- Where
- Germany
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Health Care Worker Patient Transmission, Receptor Site Alteration
Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.
The primary objective of this study is to establish differences in susceptibility to SARS CoV-2 infection among health care workers (HCW) highly exposed to patients with COVID-19 diagnosis.
- Conditions
- Health Care Worker Patient Transmission, Receptor Site Alteration, Susceptibility, Disease, Immune Response
- Trial name
- CoVEX (NCT04402827)
- Testing
- Susceptibility to infection
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas